CEimpact Podcast

Osteoporosis may be a forgotten disease – common but rarely treated. The 2023 guidelines are not here. Join host, Geoff Wall, as he reviews the new treatment recommendations and how we can optimize pharmacotherapy for all persons with osteoporosis.

The GameChanger
Osteoporosis is common and routine screenings should be implemented. Bisphosphonates are still the drug of choice, but treatment for persons over 65 should be made on a case-by-case basis.

Show Segments
00:00 - Introduction
00:25 - Background on Osteoporosis
04:17 - How Guidelines Are Formed
08:45 - Bisphosphonate Recommendation
14:14 - Denosumab Recommendation
16:40 - Anabolic Drugs
20:40 - SERMs
22:24 - The GameChanger: Recommendations Summary
27:20 - Closing Remarks


Host
Geoff Wall, PharmD, BCPS, FCCP, CGP
Professor of Pharmacy Practice, Drake University
Internal Medicine/Critical Care, UnityPoint Health

References and Resources

Pharmacologic Treatment of Primary Osteoporosis or Low Bone Mass to Prevent Fractures in Adults: A Living Clinical Guideline From the American College of Physicians.

FRAX Calculator

Redeem your CPE here
CPE (Pharmacist)

Get a membership & earn CE for GameChangers Podcast episodes (30 mins/episode)
Pharmacists: Get a membership

CE Information

Learning Objectives
Upon successful completion of this knowledge-based activity, participants should be able to:
1. Discuss the epidemiology and diagnosis of osteoporosis
2. Apply the treatment guidelines for osteoporosis to a specific patient

0.05 CEU/0.5 Hr
UAN: 0107-0000-23-063-H01-P
Initial release date: 01/06/2023
Expiration date: 01/06/2024
Additional CPE and CME details can be found here.

Follow CEimpact on Social Media:
LinkedIn
Instagram

Hydrochlorothiazide is the go-to thiazide for hypertension control despite better data for chlorthalidone. Join host Geoff Wall as he evaluates the new randomized controlled study to determine what is the best thiazide.

The GameChanger
Several pharmacologic differences exist between hydrochlorothiazide and chlorthalidone. The new DCP Study did not find any differences in cardiovascular outcomes.

Show Segments
00:00 - Introductions
02:20 - History of HCTZ vs Chlorthalidone
05:26 - The Diuretic Comparison Project: HCTZ vs Chlorthalidone
12:27 - The GameChanger: DCP Results
19:48 - Connecting to Practice: Choosing Between the Two
21:47 - Closing Remarks


Host
Geoff Wall, PharmD, BCPS, FCCP, CGP
Professor of Pharmacy Practice, Drake University
Internal Medicine/Critical Care, UnityPoint Health

References and Resources
Chlorthalidone vs. Hydrochlorothiazide for Hypertension-Cardiovascular Events.

Redeem your CPE or CME here
CPE (Pharmacist)
CME (Physician)

Get a membership & earn CE for GameChangers Podcast episodes (30 mins/episode)
Pharmacists: Get a membership
Prescribers: Get a membership

CE Information

Learning Objectives
Upon successful completion of this knowledge-based activity, participants should be able to:
1. Discuss the pharmacologic differences of hydrochlorothiazide and chlorthalidone
2. Apply the results of the DCP Study to clinical practice

0.05 CEU/0.5 Hr
UAN: 0107-0000-23-025-H01-P
Initial release date: 01/30/2023
Expiration date: 01/30/2024
Additional CPE and CME details can be found here.

Follow CEimpact on Social Media:
LinkedIn
Instagram

Results from early COVID-19 studies are still emerging. Some micronutrients, such as zinc, have been shown to decrease the severity of viral infections yet human data is sparse. Join host, Geoff Wall, as he evaluates a new study looking at the proposed benefit of zinc in COVID-19 infections.

The GameChanger
Zinc has several antiviral properties. A recent trial showed a decreased risk of ICU admission – however, has numerous exclusion criteria impacting the external validity.

Show Segments
00:00 - Introductions
01:45 - Zinc Role In COVID-19
04:20 - Looking at the Study
10:33 - The GameChanger: Study Results
19:03 - Connecting to Practice: Applicability of Exclusions
21:48 - Closing Remarks


Host
Geoff Wall, PharmD, BCPS, FCCP, CGP
Professor of Pharmacy Practice, Drake University
Internal Medicine/Critical Care, UnityPoint Health

References and Resources

• Twice-Daily Oral Zinc in the Treatment of Patients With Coronavirus Disease 2019: A Randomized Double-Blind Controlled Trial, Clinical Infectious Diseases
• A Potential Role for Zinc to Enhance Treatment for Coronavirus Disease 2019 (COVID-19)

Redeem your CPE or CME here
CPE (Pharmacist)
CME (Physician)

Get a membership & earn CE for GameChangers Podcast episodes (30 mins/episode)

Pharmacists: Get a membership
Prescribers: Get a membership

CE Information

Learning Objectives
Upon successful completion of this knowledge-based activity, participants should be able to:
1. Discuss the putative role of zinc in treating COVID-19
2. Describe the application of the results of the Zinc COVID-19 study

0.05 CEU/0.5 Hr
UAN: 0107-0000-23-025-H01-P
Initial release date: 01/23/2023
Expiration date: 01/23/2024
Additional CPE and CME details can be found here.

Follow CEimpact on Social Media:
LinkedIn
Instagram

Sometimes teaching isn't "telling" but "asking" - asking questions that encourage students and residents to problem-solve in a stepwise manner. Listen in as we discuss a teaching strategy that builds confidence and encourages curiosity in your learners.

We’ve all heard students and residents complain about ‘pimping’ from preceptors during rotations or during their residency experience. Pimping has given a bad name to what can truly be a very effective teaching strategy when done right – Socratic Questioning.  

In this month's episode, I’m speaking with Lindsay Davis of Midwestern University – Glendale, and Kevin Carrasco, a preceptor who has jumped on the Socratic Questioning bandwagon after experiencing what a difference it has made in his effectiveness as a preceptor. During our conversation – they debunked many of the assumptions often made about Socratic questioning as a teaching method and also gave some great advice on how to approach this method in a trusting and safe way for learners.

Download this pocket guide, then listen in to get started! 

Host
Kathy Schott, PhD
CEimpact
 
Guests
Lindsay Davis
Lindsay E. Davis, PharmD, BCPS, BCCP, FCCP
Director, Cardiology & Metabolism Team
Pfizer, Internal Medicine Field Medical Group
Adjunt Professor, Pharmacy Practice
Midwestern University - Glendale

Kevin Carrasco, Pharm.D., MPH
Emergency Medicine Pharmacist
Banner Univeristy Phoenix Pharmacy

Dr. Davis reports that she is employed by Pfizer. All relevant financial relationships have been mitigated.

Get CE
Click here to access the course

CE Information

At the end of this course, preceptors will be able to:

1.     Define the concept of 'microaggression'

2.     Identify strategies to support students who may experience microaggressions during experiential learning

UAN: 0107-0000-23-058-H99-P
Release Date: 01/18/2022
Expiration Date: 01/18/2025
The speakers have no relevant financial relationships with ineligible companies to disclose.

This program has been:

• Approved by the Minnesota Board of Pharmacy as education for Minnesota pharmacy preceptors.
• Reviewed by the Texas Consortium on Experiential Programs and has been designated as preceptor education and training for Texas preceptors.

Want more information on this and related topics? 

 Check out this free resource to guide the implementation of Socratic Questioning in your teaching. 

 As always, be sure to check out the full library of courses available for preceptors on the CEimpact website. Be sure to ask your experiential program director if you are a member so that you can access it all for free!0

Follow CEimpact on Social Media:
LinkedIn
Instagram

Celiac disease is of the most common auto-immune diseases in the world. The only current treatment is maintaining a strict gluten-free diet. Join host, Geoff Wall, as he discusses the results of a phase 2 study investigating a novel pharmacologic treatment of Celiac disease.

The GameChanger
Celiac disease is common and has a myriad of symptoms. A new drug may offer a way for patients with Celiac disease to eat gluten without issue.

Show Segments
00:00 - Introductions
00:50 - The Effects of Celiac Disease
03:45 - Why Celiac Causes Problems
09:08 - Latiglutenase Study Background
14:48 - The GameChanger: Latiglutenase Study Results
19:11 - Connecting to Practice
21:31 - Closing Remarks


Host
Geoff Wall, PharmD, BCPS, FCCP, CGP
Professor of Pharmacy Practice, Drake University
Internal Medicine/Critical Care, UnityPoint Health

References and Resources

Murray JA, Syage JA, Wu TT, et al. Latiglutenase Protects the Mucosa and Attenuates Symptom Severity in Patients With Celiac Disease Exposed to a Gluten Challenge. Gastroenterology. 2022 Dec;163(6):1510-1521.e6. doi: 10.1053/j.gastro.2022.07.071. Epub 2022 Aug 2. PMID: 35931103; PMCID: PMC9707643.

Redeem your CPE or CME here

• CPE (Pharmacist)
• CME (Physician) 

Get a membership & earn CE for GameChangers Podcast episodes (30 mins/episode)

• Pharmacists: Get a membership
• Prescribers: Get a membership

CE Information

Learning Objectives
Upon successful completion of this knowledge-based activity, participants should be able to:
1. Describe the extraintestinal manifestations of Celiac disease
2. Discuss the Murray et al study and its implications in patients with Celiac disease

0.05 CEU/0.5 Hr
UAN: 0107-0000-23-024-H01-P
Initial release date: 01/16/2023
Expiration date: 01/16/2024
Additional CPE and CME details can be found here.

Follow CEimpact on Social Media:
LinkedIn
Instagram

The American Diabetes Association Standards of Care in Diabetes are a “living” guideline – the recommendations are updated throughout the year and major revisions occur in January. In this episode, guest host, Jake Galdo, is joined by Susan Cornell as they evaluate new pharmacotherapy recommendations in the ADA Standards of Care.

The GameChanger
Treatment recommendations for diabetes are no longer metformin plus. Now initial, and augmented therapy, is driven by comorbid conditions.

Show Segments
00:00 - Introductions
02:09 - Reason for ADA Standards of Care Update
05:09 - The GameChanger: Comorbid Condition-Driven Therapy
08:32 - Connecting to Practice: Clinical Decision Points
11:13 - Diabetes Therapies Use for Weight Loss and Drawbacks
13:29 - Lifestyle Modification Suggestions
19:48 - Insulin Use According to New Guidelines
25:03 - Pharmacy Intervention Opportunity: Glucagon
26:37 - Closing Remarks


Host
John A Galdo, PharmD, MBA, BCPS, BCGP (Jake)
Director, Education Projects, CEimpact
CEO, Seguridad

Guest
Susan Cornell, BS, PharmD, CDCES, FAPhA, FADCES
Associate Director, Experiential Education
Professor, Pharmacy Practice
Midwestern University College of Pharmacy

References and Resources
Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2023. Diabetes Care

Redeem your CPE or CME here

• CPE (Pharmacist)
• CME (Physician)

Get a membership & earn CE for GameChangers Podcast episodes (30 mins/episode)

• Pharmacists: Get a membership
• Prescribers: Get a membership

CE Information

Learning Objectives
Upon successful completion of this knowledge-based activity, participants should be able to:
1. Identify the first line therapy for treatment of diabetes
2. Discuss key clinical decision points for the treatment of diabetes

0.05 CEU/0.5 Hr
UAN: 0107-0000-23-023-H01-P
Initial release date: 01/09/2023
Expiration date: 01/09/2024
Additional CPE and CME details can be found here.

Follow CEimpact on Social Media:
LinkedIn
Instagram

Stimulant medications, like methylphenidate and amphetamines, have adverse cardiovascular effects, like elevated blood pressure, increasing the risk of cardiovascular events. Join host Geoff Wall as he reviews a new meta-analysis trying to quantify the risk of ADHD medications on cardiovascular outcomes.

The GameChanger
A large meta-analysis did not find an association between medications for ADHD and cardiovascular disease. Several limitations may interfere with the applicability of these results.

Show Segments
00:00 - Introductions
01:38 - Background on ADHD and Stimulant Medications
02:58 - Rationale for Analysis
06:42 - Looking at the Meta-Analysis
11:44 - The GameChanger: Meta-Analysis Findings
17:43 - Connecting to Practice: Addressing Patient Concerns
20:00 - Closing Remarks

Host
Geoff Wall, PharmD, BCPS, FCCP, CGP
Professor of Pharmacy Practice, Drake University
Internal Medicine/Critical Care, UnityPoint Health

References and Resources
Risk of Cardiovascular Diseases Associated With Medications Used in Attention-Deficit/Hyperactivity Disorder: A Systematic Review and Meta-analysis

Redeem your CPE or CME here

• CPE (Pharmacist)
• CME (Physician)

Get a membership & earn CE for GameChangers Podcast episodes (30 mins/episode)

• Pharmacists: Get a membership
• Prescribers: Get a membership

CE Information

Learning Objectives
Upon successful completion of this knowledge-based activity, participants should be able to:
1. Describe the purported mechanism of the potential risk of cardiovascular disease in patients taking stimulant medications
2. Discuss the findings of a recent meta-analysis by Zhang et al on cardiovascular disease and stimulant medications

0.05 CEU/0.5 Hr
UAN: 0107-0000-23-016-H01-P
Initial release date: 01/03/2023
Expiration date: 01/03/2024
Additional CPE and CME details can be found here.

Follow CEimpact on Social Media:
LinkedIn
Instagram

COPD is a common and complex disease for both inpatient and outpatient providers. GOLD guidelines provide diagnosis and treatment recommendations for COPD and were recently updated. Join host Geoff Wall as he breaks down the salient recommendations in the 2023 GOLD guidelines.

The GameChanger
A new severity scoring system for COPD exists – category E. Additionally, inhaled corticosteroids may play a larger role in the pharmacotherapy of COPD.

Show Segments
00:00 - Introductions
01:40 - Background on COPD
04:09 - The GameChanger: Severity Scoring Changes
08:23 - Connecting to Practice: Impact of Inhaler Technique
16:08 - Use of Inhaled Corticosteroids
23:23 - Closing Remarks


Host
Geoff Wall, PharmD, BCPS, FCCP, CGP
Professor of Pharmacy Practice, Drake University
Internal Medicine/Critical Care, UnityPoint Health

References and Resources

• 2023 GOLD Report

Redeem your CPE or CME here

• CPE (Pharmacist) 
• CME (Physician)

Get a membership & earn CE for GameChangers Podcast episodes (30 mins/episode)

• Pharmacists: Get a membership
• Prescribers: Get a membership

CE Information

Learning Objectives
Upon successful completion of this knowledge-based activity, participants should be able to:
1. Describe the new severity scoring system for COPD in the 2023 GOLD guidelines
2. Discuss appropriate use of inhaled corticosteroids in COPD patients

0.05 CEU/0.5 Hr
UAN: 0107-0000-22-422-H04-P
Initial release date: 12/20/2022
Expiration date: 12/20/2023
Additional CPE and CME details can be found here.

Follow CEimpact on Social Media:
LinkedIn
Instagram

We’ve heard a lot about microaggressions in the past couple of years. A microaggression can include verbal, behavioral, or environmental aggressions that negatively communicate about race, culture, or gender. They can be intentional or unintentional but can negatively impact healthcare interactions – whether those involve students, residents, patients, or all of the above.

In this episode, speaking with Anisa Hansen, a clinical pharmacist who leads diversity, equity, and inclusion initiatives for the College of Pharmacy and Health Sciences at Drake. Her passion is educating learners on topics in the areas of mental health, LGBTQ health and wellness,  and equity and inclusion. Anisa has first-hand experience supporting students who have experienced microaggressions as part of their pharmacy practice experiences. Listen to learn more about how she has navigated those situations to support students.

Download this social identity mapping exercise. Don’t worry – it will make sense after you listen to the episode!

Host
Kathy Schott, PhD
CEimpact
 
Guests
Anisa Hansen, PharmD
Professor of Pharmacy Practice
Drake University College of Pharmacy and Health Sciences

Anisa Hansen, PharmD, is a Professor of Pharmacy Practice at Drake University in Des Moines, Iowa. She has a passion for educating students on mental health, wellness, LGBTQ health, and equity and inclusion. Anisa teaches a 3-credit J-Term course focused on LGBTQ Health Issues and a first-year course exploring the portrayal of mental illness and disabilities in the media. Anisa is the mental health clinical pharmacist for Iowa Lutheran Hospital. She provides clinical service, educates sixth-year pharmacy students, and provides medication education groups in outpatient and inpatient settings.

Get CE
Click here to access the course.

CE Information

At the end of this course, preceptors will be able to:

1.     Define the concept of 'microaggression'

2.     Identify strategies to support students who may experience microaggressions during experiential learning

Follow CEimpact on Social Media:
LinkedIn
Instagram

Gabapentin is often used in a multi-model pain management strategy in both peri- and post-operative setting. Little data exists looking at the adverse effects of this practice. Join host Geoff Wall, as he reviews data from a new study looking at this question.

The GameChanger
Gabapentin’s data is sparse for use in postoperative pain; however, new data suggest use after orthopedic surgery is associated with poor outcomes.

Show Segments
00:00 - Introductions
00:58 - The Current Use of Gabapentin
03:19 - Perioperative Gabapentin Study
09:34 - GameChanger: Study Findings
15:30 - Connecting to Practice: Gabapentin on Order Sets
16:52 - Closing Remarks


Host
Geoff Wall, PharmD, BCPS, FCCP, CGP
Professor of Pharmacy Practice, Drake University
Internal Medicine/Critical Care, UnityPoint Health

References and Resources
Perioperative Gabapentin Use and In-Hospital Adverse Clinical Events Among Older Adults After Major Surgery

Redeem your CPE or CME here

• CPE (Pharmacist) 
• CME (Physician) 

Get a membership & earn CE for GameChangers Podcast episodes (30 mins/episode)

• Pharmacists: Get a membership
• Prescribers: Get a membership

CE Information

Learning Objectives
Upon successful completion of this knowledge-based activity, participants should be able to:
1. Apply the results of the gabapentin study to the perioperative patient population
2. Discuss the evidence of the effectiveness of gabapentin in multi-modal pain management

0.05 CEU/0.5 Hr
UAN: 0107-0000-22-441-H04-P
Initial release date: 12/16/2022
Expiration date: 12/16/2023
Additional CPE and CME details can be found here.

Follow CEimpact on Social Media:
LinkedIn
Instagram